

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* ANIDO VICENTE JR			2. Issuer Name and Ticker or Trading Symbol AERIE PHARMACEUTICALS INC [AERI]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chief Executive Officer	
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 06/06/2018		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person	
C/O AERIE PHARMACEUTICALS, INC. 4301 EMPEROR BLVD., SUITE 400			4. If Amendment, Date of Original Filed (Month/Day/Year)			
(Street) DURHAM NC 27703						
(City) (State) (Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/06/2018		M		50,000	A	\$2.9	176,320	D	
Common Stock	06/06/2018		S		45,662	D	\$60.4442 ⁽¹⁾	130,658	D	
Common Stock	06/06/2018		S		4,338	D	\$61.0981 ⁽²⁾	126,320	D	
Common Stock	06/07/2018		M		50,000	A	\$2.9	176,320	D	
Common Stock	06/07/2018		S		33,614	D	\$62.0562 ⁽³⁾	142,706	D	
Common Stock	06/07/2018		S		16,386	D	\$62.8031 ⁽⁴⁾	126,320	D	
Common Stock	06/08/2018		M		23,861	A	\$2.9	150,181	D	
Common Stock	06/08/2018		M		26,139	A	\$3.15	176,320	D	
Common Stock	06/08/2018		S		20,283	D	\$63.3498 ⁽⁵⁾	156,037	D	
Common Stock	06/08/2018		S		29,717	D	\$64.5207 ⁽⁶⁾	126,320	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Option (Right to Buy)	\$2.9	06/06/2018		M			50,000	12/21/2016	03/21/2023	Common Stock	50,000	\$0.00	73,861	D	
Option (Right to Buy)	\$2.9	06/07/2018		M			50,000	12/21/2016	03/21/2023	Common Stock	50,000	\$0.00	23,861	D	
Option (Right to Buy)	\$2.9	06/08/2018		M			23,861	12/21/2016	03/21/2023	Common Stock	23,861	\$0.00	0	D	
Option (Right to Buy)	\$3.15	06/08/2018		M			26,139	09/12/2017	09/12/2023	Common Stock	26,139	\$0.00	896,329	D	

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold pursuant to the reporting person's Rule 10b5-1 plan in multiple transactions at prices ranging from \$60.00 to \$60.975, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes to this Form 4.
2. The price reported in Column 4 is a weighted average price. These shares were sold pursuant to the reporting person's Rule 10b5-1 plan in multiple transactions at prices ranging from \$61.00 to \$61.20, inclusive.
3. The price reported in Column 4 is a weighted average price. These shares were sold pursuant to the reporting person's Rule 10b5-1 plan in multiple transactions at prices ranging from \$61.50 to \$62.425, inclusive.
4. The price reported in Column 4 is a weighted average price. These shares were sold pursuant to the reporting person's Rule 10b5-1 plan in multiple transactions at prices ranging from \$62.45 to \$63.325, inclusive.
5. The price reported in Column 4 is a weighted average price. These shares were sold pursuant to the reporting person's Rule 10b5-1 plan in multiple transactions at prices ranging from \$62.95 to \$63.85, inclusive.
6. The price reported in Column 4 is a weighted average price. These shares were sold pursuant to the reporting person's Rule 10b5-1 plan in multiple transactions at prices ranging from \$64.20 to \$65.00, inclusive.

Remarks:

/s/ Richard J. Rubino,
Attorney-in-Fact for Vicente 06/08/2018
Anido, Jr.

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.